Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced an effective date for its previously-announced share consolidation. At its Annual General and Special Meeting of Shareholders, which was held on November 12, 2024, Psyence Biomed's shareholders approved a consolidation of the Company's common shares at a ratio of up to 1 common share for every 75 common shares held, with the final ratio to be determined by the Company's board of directors (the "Board"). Also, as previously announced, the Board approved a 1-for-75 consolidation of its outstanding common shares.

The Company's common shares will begin trading on a post-consolidated basis at the opening of the market on Tuesday, November 26, 2024. Following the consolidation, the Company's common shares will continue to trade under the symbol 'PBM' with the new CUSIP number 74449F209. The consolidation is part of the Company's plan to regain compliance with the minimum bid price requirement of Nasdaq Listing Rule 5450(a)(1) (the "Nasdaq Rule 5450") for continued listing on The Nasdaq Global Market.